Eye

The last place anyone wants to have an ophthalmic emergency is standing on top of Mount Kilimanjaro in Tanzania, at 19,341 feet above sea level and days from any medical care.

Vevye, a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, is now available in the U.S., according to a manufacturer press release.

Okyo Pharma announced positive safety and efficacy data from its phase 2 trial of OK-101 ophthalmic solution, a lipid-conjugated chemerin peptide agonist designed to reduce pain and inflammation in patients with dry eye disease.

K2 Medical Research has partnered with Magruder Eye Institute and RetiSpec in a research pilot to improve access to clinical trials, using AI-driven technology to prescreen eligible candidates in an eye care setting.

Alimera Sciences has completed enrollment for its Synchronicity study, a prospective, open-label trial to evaluate the safety and efficacy of Yutiq for chronic noninfectious uveitis and related inflammation.

VSP Vision has launched AARP Vision Plans from VSP, which includes a number of vision and eye wear insurance options tailored to the needs of AARP members.

Stuart Therapeutics has announced the first patient first visit for its phase 3 clinical trial of ST-100 ophthalmic solution for patients with dry eye disease.

The office-based thermal eyelid treatment TearCare significantly improved tear breakup time and measures of meibomian gland secretion compared with Restasis in patients with dry eye disease, according to 6-month trial data.

Nicox announced that the first patient has been screened in its Whistler phase 3b clinical trial of NCX 470, a nitric oxide-donating bimatoprost eye drop designed to lower IOP in patients with open-angle glaucoma or ocular hypertension.

Azura Ophthalmics announced positive topline results from its phase 2 study of AZR-MD-001 in patients with contact lens discomfort and signs of meibomian gland dysfunction.